Boston Scientific Corporation · NYSE:BSX
Boston Scientific — Merger or Acquisition (October 2021)
11 slides from Boston Scientific's merger presentation, Oct 6, 2021
Slide 1: Baylis Medical Company Acquisition
Baylis Medical Company Acquisition October 6, 2021
Slide 2: Safe Harbor and other disclaimers
Safe Harbor and other disclaimers Safe harbor for forward-looking statements: This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by
Slide 3: Regulatory disclaimers
Regulatory disclaimers FARAPULSE™ PFA system CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale. Millipede mitral repair technology U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investiga
Slide 4: BSX and Baylis Medical Company
BSX and Baylis Medical Company ➢ Global competitor in left-heart therapies within Electrophysiology ➢ Leader in technologies that (EP) and Structural Heart enable left-heart access and therapy delivery ➢ Comprehensive EP portfolio, Expanded including Rhythmia™, StablePoint™, PolarX™ and leadership i
Slide 5: BSX to Acquire Baylis Medical Company
BSX to Acquire Baylis Medical Company • Broad portfolio of cardiac access and therapy delivery solutions Baylis Medical - A global leader in transseptal needles with innovative radiofrequency devices Overview • Privately held company founded in 1986 • ~800 employees in acquired business. Headquarter
Slide 6: Strategic Rationale
Strategic Rationale High Sales Synergy Expand US Market Integrated Solutions Global Expansion Reach Critical part of EP Baylis products are sold in Technology integration BSX global footprint Ablation, LAAC, and most hospitals with EP and opportunity enables accelerates international Mitral procedur
Slide 7: Product Overview – Transseptal Needles
Product Overview – Transseptal Needles Procedure Baylis Medical Mitral LAAC AFib Ablation ► Transseptal puncture (TSP) needles facilitate access to the ► Baylis’ RF needles and wires: heart’s left side and are used in nearly all catheter-delivered • Improve safety, ease of use, and enable more left-
Slide 8: Baylis Medical Key Products & Solutions
Baylis Medical Key Products & Solutions Latest RF crossing platform that adds efficiency and safety through streamlining workflow and reducing tools required More than one million systems sold - Clinically proven to provide safer and more predictable crossing compared to traditional needles Sheaths,
Slide 9: Market and Portfolio Overview
Market and Portfolio Overview Expansion of BSX Electrophysiology and Structural Heart Portfolios Addressable Market Expansion EP Ablations Access Solutions ~$13B POLARx™ FARAPULSE™ Pulsed Cryoablation Catheter Field Ablation System ~$8B RHYTHMIA HDx™ Mapping System STABLEPOINT™ Force-Sensing NRG® RF
Slide 10: Growth Accretive and Meaningful Strategic Synergies Expected
Growth Accretive and Meaningful Strategic Synergies Expected Furthers category leadership strategy in left-heart procedures Category • Access portfolio complementary to existing BSX EP and Structural Heart portfolios Leadership • Adds global market leader in left-heart access, including novel RF tra
Slide 11: Thank you
WHEN WE CHALLENGE, WE ADVANCE Baylis Medical Company Acquisition Thank you
Boston Scientific — Merger or Acquisition (October 2021) on 6ix